Direct Meds™ Official Site | Natural Supplement for Immune Health, Weight Management & Daily Wellness

These statements have not been evaluated by the Food and Drug Administration. Direct Meds is not intended to diagnose, treat, cure, or prevent any disease.

Direct Meds is a dietary supplement manufactured in compliance with the Dietary Supplement Health and Education Act of 1994 (DSHEA), the federal law that governs how dietary supplements are produced, labeled, and marketed in the United States. Under DSHEA, dietary supplements do not require FDA pre-market approval. Manufacturers carry legal responsibility for ensuring product safety and the accuracy of all labeling before bringing a supplement to market.

Important Distinction: Direct Meds vs. Prescription GLP-1 Medications

Direct Meds is a dietary supplement, not a pharmaceutical drug. Prescription GLP-1 receptor agonists such as semaglutide (marketed as Ozempic, Wegovy, and Rybelsus by Novo Nordisk), liraglutide (Victoza, Saxenda by Novo Nordisk), and tirzepatide (Mounjaro and Zepbound by Eli Lilly) are FDA-approved drugs regulated under the Federal Food, Drug, and Cosmetic Act (FD&C Act). These medications require a valid prescription from a licensed healthcare provider and are subject to full FDA drug approval processes, including Phase I through Phase III clinical trials, post-market safety surveillance, and Risk Evaluation and Mitigation Strategies (REMS) where applicable.

Direct Meds contains natural botanical ingredients that published research suggests may support the body’s own GLP-1 metabolic pathways, including berberine and its documented AMPK activation properties. These ingredients do not constitute pharmaceutical GLP-1 receptor agonists and do not carry the same regulatory classification, clinical indications, approved uses, or side effect profile as prescription GLP-1 drugs. Direct Meds makes no claim to replicate, replace, or perform equivalently to any FDA-approved prescription medication.

Individuals currently prescribed a GLP-1 medication or any prescription drug for weight management, type 2 diabetes, or metabolic conditions must consult their prescribing physician before adding Direct Meds or any dietary supplement to their regimen.

Facility Standards

Every batch of Direct Meds is produced in an FDA-registered manufacturing facility that holds Good Manufacturing Practice (GMP) certification. GMP standards, as defined under 21 CFR Part 111, require documented manufacturing procedures, raw material testing, in-process controls, and finished product verification at every stage of production. These standards exist to protect consumers from contamination, mislabeling, and under-potency products.

Third-Party Testing

Direct Meds undergoes independent third-party laboratory testing for:

• Ingredient identity and purity confirmation
• Dosage accuracy and potency verification
• Absence of heavy metals including lead, arsenic, mercury, and cadmium
• Microbial safety in line with established food safety standards
• Absence of undeclared pharmaceutical compounds, including synthetic GLP-1 agents or prescription weight loss drugs

Labeling Compliance

All product claims and label content on Direct Meds comply with FDA regulations under 21 CFR Part 101, which covers dietary supplement labeling requirements. No claim made on the Direct Meds website or packaging constitutes a drug claim or disease claim under FDA definitions. Structure and function claims, where present, follow the disclosure guidelines set by the FDA under 21 CFR Part 101.93.

Who Should Consult a Doctor First

If you currently take prescription medication, manage a chronic health condition such as type 2 diabetes or obesity, have undergone recent surgery, or are pregnant or breastfeeding, consult a licensed healthcare provider before starting Direct Meds or any new dietary supplement.

Where to Learn More

For the most current FDA guidance on dietary supplements, consumer safety information, and how to report an adverse event, visit:

www.fda.gov/food/dietary-supplements

For FDA information on approved GLP-1 receptor agonist medications including semaglutide, visit:

www.fda.gov/drugs

For GMP standards governing dietary supplement manufacturing, see 21 CFR Part 111 at:

www.ecfr.gov

Direct Meds is not affiliated with the FDA, Novo Nordisk, Eli Lilly, or any pharmaceutical company. All regulatory references are provided for transparency and consumer education purposes only.